Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07376317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)

Study acronym: OTIMAS
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls.
Trial Details
NCT Number NCT07376317
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions
(from sponsor)		 Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma, Stage IV Melanoma
Related terms Melanoma
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov